Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease

Niu, Xiaolu; Liu, Li; Song, Zhixiu; Li, Qing; Wang, Zhihua; Zhang, Jianlong; Li, Hehua

doi:10.1007/s00702-016-1612-8

Cited by 59 publications

(44 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies used lactulose or glucose breath tests to detect SIBO, with sensitivities of 31–68% and 29–93%, respectively, and specificities of 44–100% and 30–86%, respectively [115]. Bloating and flatulence [112,113] have been reported to be associated with SIBO in PD in some studies, whereas constipation and tenesmus were reported in one study [114]. The relationship between PD symptoms and SIBO is heterogeneous among reports.…”

Section: Altered Gut Microbiome In Patients With Pdmentioning

confidence: 99%

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Chiang

Lin

2019

JMD

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a common neurodegenerative disorder arising from an interplay between genetic and environmental risk factors. Studies have suggested that the pathological hallmarks of intraneuronal α-synuclein aggregations may start from the olfactory bulb and the enteric nervous system of the gut and later propagate to the brain via the olfactory tract and the vagus nerve. This hypothesis correlates well with clinical symptoms, such as constipation, that may develop up to 20 years before the onset of PD motor symptoms. Recent interest in the gut–brain axis has led to vigorous research into the gastrointestinal pathology and gut microbiota changes in patients with PD. In this review, we provide current clinical and pathological evidence of gut involvement in PD by summarizing the changes in gut microbiota composition and gut inflammation associated with its pathogenesis.

show abstract

Section: Altered Gut Microbiome In Patients With Pdmentioning

confidence: 99%

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Chiang

Lin

2019

JMD

View full text Add to dashboard Cite

show abstract

“…Future study is needed to elucidate it. Moreover, gastrointestinal infections, such as Helicobacter pylori and small intestinal bacterial overgrowth in PD (31,32), have potentially relevant effects on body weight and neurogastrointestinal hormones. However, leptin, ghrelin and GLP-1 may not play a major role in altered body composition in PD (21).…”

Section: Discussionmentioning

confidence: 99%

Sarcopenia in Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) and sarcopenia are two common diseases in aging people. To date, the prevalence of sarcopenia in PD patients and the relationship between clinical features and sarcopenia in PD patients are not clear. The aim of the study was to (1) assess the prevalence of sarcopenia in PD patients and (2) reveal the clinical features between PD patients with and without sarcopenia.Method: A systematic review was carried out through screening PubMed, EMBASE, and Cochrane database in May 2020. All study designs (case–control, cohort, and cross-sectional studies) were eligible for meta-analysis. Data of patients' characteristics, sarcopenia criteria, sarcopenia prevalence, and sarcopenia measures were retrieved. The primary outcome was estimated prevalence of sarcopenia by a pooled prevalence (%) and its 95% confidence interval (CI), using a random-effects model. The secondary outcome was the differences in clinical features between PD patients with and without sarcopenia by meta-analysis. Included articles were assessed for risk of bias. Potential sources of variation were investigated by using subgroup analyses and meta-regression.Result: Ten studies were included in the review. Among them, nine were cross-sectional studies, and one was a prospective cohort study. Age of participants with PD in the studies ranged from 51.1 to 80.7 years. The estimated prevalence of sarcopenia ranged from 6 to 55.5%. The random-effects pooled prevalence was 29% (95% CIs: 0.18–0.40). When only studies at low risk of bias were considered, pooled prevalence decreased to 17% (95% CIs: 0.02–0.33), with still high heterogeneity. The incidence of falls in PD patients with sarcopenia was higher than that in PD patients without sarcopenia. There was no difference in sex ratio between PD patients with and without sarcopenia.Conclusion: Sarcopenia seems to be common in patients with PD. Early assessment of sarcopenia should be implemented in PD to avoid fall and disability.

show abstract

“…A small intestinal bacterial overgrowth (SIBO), a disorder with excessive bacterial growth in the small intestine, has also been reported in PD patients with a prevalence varying from 25% to 67% [52–55]. SIBO has been associated with gastrointestinal symptoms and worse motor scores (UPDRS III) [54, 55] while there is inconsistency regarding its effects on motor fluctuations [52, 54, 55]. SIBO might cause changes in intestinal permeability and contribute to an increase in bacterial translocation and consequently induction of an inflammatory response in the host [56].…”

Section: Chronic Inflammation In Parkinson's Diseasementioning

confidence: 99%

Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions

Kalampokini

Becker

Faßbender

et al. 2019

Parkinson's Disease

View full text Add to dashboard Cite

Neuroinflammation is increasingly recognized as an important pathophysiological feature of neurodegenerative diseases such as Parkinson’s disease (PD). Recent evidence suggests that neuroinflammation in PD might originate in the intestine and the bidirectional communication between the central and enteric nervous system, the so-called “gut-brain axis,” has received growing attention due to its contribution to the pathogenesis of neurological disorders. Diet targets mediators of inflammation with various mechanisms and combined with dopaminergic treatment can exert various beneficial effects in PD. Food-based therapies may favorably modulate gut microbiota composition and enhance the intestinal epithelial integrity or decrease the proinflammatory response by direct effects on immune cells. Diets rich in pre- and probiotics, polyunsaturated fatty acids, phenols including flavonoids, and vitamins, such as the Mediterranean diet or a plant-based diet, may attenuate chronic inflammation and positively influence PD symptoms and even progression of the disease. Dietary strategies should be encouraged in the context of a healthy lifestyle with physical activity, which also has neuroimmune-modifying properties. Thus, diet adaptation appears to be an effective additive, nonpharmacological therapeutic strategy that can attenuate the chronic inflammation implicated in PD, potentially slow down degeneration, and thereby modify the course of the disease. PD patients should be highly encouraged to adopt corresponding lifestyle modifications, in order to improve not only PD symptoms, but also general quality of life. Future research should focus on planning larger clinical trials with dietary interventions in PD in order to obtain hard evidence for the hypothesized beneficial effects.

show abstract

Prevalence of small intestinal bacterial overgrowth in Chinese patients with Parkinson’s disease

Cited by 59 publications

References 25 publications

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease

Sarcopenia in Patients With Parkinson's Disease: A Systematic Review and Meta-Analysis

Nonpharmacological Modulation of Chronic Inflammation in Parkinson’s Disease: Role of Diet Interventions

Contact Info

Product

Resources

About